Home - Australian Pharmacist

Breathing change into asthma care

Sian Powell - September 3, 2000

Industry

Updated guidelines in the Australian Asthma Handbook were released in September 2025 with SABA-only therapy now considered risky in adults and adolescents.

Metformin for wet (neovascular) age-related macular degeneration

Dr Esther Lau and Prof Lisa Nissen - June 12, 2000

CPD

References Khanna S, Shaw L, Hyman MJ, et al. Association of metformin use with risk of newly onset neovascular age-related macular degeneration development. Retina...

Changes to AIR information

AP Staff - April 18, 2000

Clinical

References 1. Australian Government Department of Health and Aged Care. Mandatory reporting changes to the Australian Immunisation Register (AIR) from 1 March 2024. 2024. At:...

Treatment of acute pain with Pharmacist Only (S3) celecoxib

AP Staff - June 5, 2000

CPD

Long-acting treatment for opioid dependence approved

Ruth Cooper - December 10, 2018

Clinical

The first long-acting treatment for opioid dependence has been approved for use in Australia by the Therapeutic Goods Administration (TGA). Buvidal Weekly and Buvidal Monthly...

References Australian Government Australian Institute of Health and Welfare. Heart, stroke and vascular disease: Australian facts. 2024. At: www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/summary?__cf_chl_tk=rdBRmK8d0ESsnzGKoxqSoPhYhF5k0SQmw4_CJ9ue5W8-1739941894-1.0.1.1-RJSLYVVhq7aZmxXJ1v11vQsTEUjubu3_JSoRUz5Z8RQ AusCVDRisk. Australian CVD risk calculator. 2023....

1...311312313...317 Page 312 of 317

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

What motivated you to seek election as the next PSA National President?

What do you hope to achieve as PSA President?

Why do you feel this is such a pivotal moment for PSA and the profession?

What are the major challenges pharmacists are facing right now?

How do you see the profession evolving in 5 years?

How have your background and previous experiences shaped your views of the profession?

Case scenario

Learning objectives

Introduction

Aetiology and pathophysiology

Clinical features

Diagnosis, differential diagnosis and prognosis

Management and treatment

Knowledge to practice

Conclusion

Case scenario continued

Key points

References

Our authors

Our reviewer

Conflict of interest declaration

Wrong-patient supply leads to hospital admission

Labelling and selection errors

A stronger incident-reporting culture

Building a career in incident management

ALERT 1: Potential risk of suicidal thoughts

What does the product warning say?

What products are affected by this alert?

What should pharmacists do?

ALERT 2: Tirzepatide (Mounjaro) and contraception

Is it just tirzepatide (Mounjaro)?

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

What motivated you to seek election as the next PSA National President?

What do you hope to achieve as PSA President?

Why do you feel this is such a pivotal moment for PSA and the profession?

What are the major challenges pharmacists are facing right now?

How do you see the profession evolving in 5 years?

How have your background and previous experiences shaped your views of the profession?

Case scenario

Learning objectives

Introduction

Aetiology and pathophysiology

Clinical features

Diagnosis, differential diagnosis and prognosis

Management and treatment

Knowledge to practice

Conclusion

Case scenario continued

Key points

References

Our authors

Our reviewer

Conflict of interest declaration

Wrong-patient supply leads to hospital admission

Labelling and selection errors

A stronger incident-reporting culture

Building a career in incident management

ALERT 1: Potential risk of suicidal thoughts

What does the product warning say?

What products are affected by this alert?

What should pharmacists do?

ALERT 2: Tirzepatide (Mounjaro) and contraception

Is it just tirzepatide (Mounjaro)?

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

**ALERT 2: Tirzepatide (Mounjaro) and contraception**

**ALERT 2: Tirzepatide (Mounjaro) and contraception**

**ALERT 2: Tirzepatide (Mounjaro) and contraception**